Insulin resistance pathway

The **insulin resistance pathway** refers to a complex network of molecular events that result in reduced cellular responsiveness to normal circulating concentrations of insulin. This phenomenon is central to the pathogenesis of type 2 diabetes mellitus and metabolic syndrome. The core defect involves impaired signal transduction downstream of the **insulin receptor**, particularly affecting key nodes such as **insulin receptor substrate proteins** (IRS), phosphatidylinositol 3‐kinase (**PI3K**), Akt/protein kinase B (**Akt/PKB**), and downstream effectors like GLUT transporters responsible for glucose uptake into cells.[1][2][3] Disruption can occur at multiple points—receptor level mutations/abnormalities,[4] post-receptor defects including altered phosphorylation states,[7] increased serine/threonine phosphorylation of IRS proteins,[2] lipid accumulation interfering with signaling intermediates,[5] chronic inflammation, oxidative stress, ceramide accumulation,[4] and other metabolic derangements. Because "insulin resistance pathway" describes an entire biological process rather than an individual gene product or protein target typically considered "druggable," it is not classified as a canonical therapeutic target like receptors or enzymes.[6] In summary: The term “insulin resistance pathway” does not refer to a single molecule but encompasses multiple interacting proteins and regulatory steps involved in mediating cellular responses—or lack thereof—to insulin. Therefore it should not be treated as an individual drug target entity for structured databases; instead focus should be placed on specific molecules within this network such as “Insulin receptor,” “Insulin receptor substrate 1,” etc., which are valid targets with defined properties.[6] If you need information about specific components within this pathway—such as "Insulin receptor," "IRS‐1," etc.—please specify so detailed structured data can be provided for those entities.

Other names

Insulin resistance signaling pathwayInsulin resistance mechanismIR pathway

Drugs targeting this pathway act via various mechanisms, such as: - Enhancing insulin receptor sensitivity/metabolic signaling (metformin, thiazolidinediones)[4] - Increasing glucose uptake in peripheral tissues by promoting GLUT translocation to the membrane[3][7] - Reducing hepatic glucose production (metformin) - Modulating incretin effect and insulin secretion (GLP‑1 agonists)